NIH R01 · 2025
Supramolecular biomaterials for tuning the inflammatory properties of the complement system
Complement inhibitors are receiving significant interest currently towards inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, primarily in the form of monoclonal antibodies against the terminal products of complement activation most responsible for harmful inflammation. However, monoclonal antibody therapeutics are largely falling short of providing a broadly useful tool for inflammatory disease because they are rapidly cleared, have variable efficacy in broad patient populations, are expensive, and require regular infusions to maintain therapeutic concentrations. Cyclical dosing further induces the formation of anti-drug antibodies, and monoclonal antibody…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.